Nano cap Sonnet BioTherapeutics Holdings (SONN +87%)
rockets northward on a healthy 26x surge in volume in apparent response
to a report from New York think tank Altru Institute which has
organized the Altru Global Virus Project aimed at identifying breakthroughs to treat COVID-19.
Altru’s first summary report focuses on Sonnet and
its proprietary platform that may be “highly applicable” to the
treatment of viral infections.
The company says its technology, called Fully Human Albumin Binding,
enables modular plug-and-play drug development. Specifically, it
utilizes a scaffold, based on its proprietary albumin-binding
single-chain antibody fragment, to deliver recombinant human cytokines
and other targets. Once administered into the body, the albumin-binding
fragment attaches to albumin
in the bloodstream and accumulates in inflamed tissue including,
potentially, inflamed lung tissue in COVID-19 patients with respiratory
problems.
Albumin, made by the liver, comprises ~60% of the total protein in the blood.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.